AR063332A1 - Derivados de imidazolona e imidazolidinona como inhibidores de la 11b-hsd1, un proceso de preparacion y una composicion farmaceutica en base al compuesto - Google Patents
Derivados de imidazolona e imidazolidinona como inhibidores de la 11b-hsd1, un proceso de preparacion y una composicion farmaceutica en base al compuestoInfo
- Publication number
- AR063332A1 AR063332A1 ARP070104597A ARP070104597A AR063332A1 AR 063332 A1 AR063332 A1 AR 063332A1 AR P070104597 A ARP070104597 A AR P070104597A AR P070104597 A ARP070104597 A AR P070104597A AR 063332 A1 AR063332 A1 AR 063332A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- haloalkyl
- substituted
- independently selected
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/10—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Estos compuestos se pueden emplear como medicamentos para el tratamiento de la diabetes, dislipitemias, obesidad e hipertension. 1. Los compuestos de formula (1) en la que R1 es a) bornilo, norbornilo, adamantilo o adamantilo sustituido con uno o dos sustituyentes seleccionados independientemente de entre los siguientes: hidroxi, alcoxi, halogeno, alquilo, hidroxialquilo, amino, aminocarbonilo, alcoxicarbonilo, hidroxicarbonilo, alquilcarbonilamino, alquil-S(O)2-amino, haloalquil-S(O)2- amino, alcoxicarbonilamino-S(O)2-amino, amino-S(O)2-amino, hidroxialquilcarbonilamino, aminocarbonilamino y haloalcoxi; b) trifluorometilfenilo, metoxifenilo, haloalcoxifenilo o difluorofenilo, en el que trifluorometilfenilo, haloalcoxifenilo y difluorofenilo se sustituyen opcionalmente con uno o dos sustituyentes seleccionados independientemente de entre los siguientes: alquilo, halogeno, haloalquilo, alcoxi, hidroxi y haloalcoxi; c) trifluorometilfenilalquilo o trifluorometilfenilalquilo sustituidos con uno o dos sustituyentes seleccionados independientemente de entre los siguientes: alquilo, halogeno, haloalquilo, alcoxi, hidroxi y haloalcoxi; d) fenilcicloalquilo o fenilcicloalquilo sustituido con un numero de sustituyentes de uno a tres seleccionados independientemente de entre los siguientes alquilo, halogeno, haloalquilo, alcoxi, hidroxi y haloalcoxi; e) cianofenilo o cianofenilo sustituido con halogeno; o f) dihalofenilo, aminocarbonilfenilo o hidroxifenilo, en el que el aminocarbonilfenilo y el hidroxifenilo se sustituyen opcionalmente con uno o dos sustituyentes seleccionados independientemente de entre los siguientes: alquilo, halogeno, haloalquilo, alcoxi y haloalcoxi; R2 es hidrogeno, alquilo, alquenilo, haloalquilo, piridinilalquilo, cicloalquilo, cicloalquiloalquilo o fenilalquilo, o R2 es piridinilalquilo o fenilalquilo en que ambos están sustituidos con un numero de sustituyentes de uno a tres seleccionados independientemente de entre los siguientes: alquilo, hidroxi, alcoxi, halogeno, haloalquilo y haloalcoxi; uno entre R3 y R4 es hidrogeno, alquilo, cicloalquilo, haloalquilo o no existe y el otro es: a) hidrogeno, alquilo, piridinilo, cicloalquilo, cicloalquilalquilo o haloalquilo; b) fenilo o fenilo sustituido con un numero de sustituyentes de uno a tres seleccionados independientemente de entre los siguientes fluoro, cloro, bromo, haloalquilo, alcoxi, hidroxi, haloalquilo y haloalcoxi; c) fenilalquilo o piridinilalquilo en que el fenilalquilo y el piridinilalquilo se sustituyen opcionalmente con un numero de sustituyentes de uno a tres seleccionados independientemente de entre los siguientes alquilo, halogeno, haloalquilo e hidroxi; d) oxetano u oxetano sustituido con un grupo alquilo; e) naftilo o tetrahidronaftilo; f) fenilalcoxialquilo o fenilalcoxialquilo sustituido con un numero de sustituyentes de uno a tres seleccionados independientemente de entre los siguientes: alquilo y halogeno; g) hidroxialquilo; o h) piridiniloxialquilo o piridiniloxialquilo sustituido con un grupo ciano; o R3 y R4 junto con el átomo de carbono al que están unidos forman un cicloalcano, piperidina, tetrahidropirano, tetrahidrotiopirano, pirrolidina, tetrahidrofurano, indano u oxetano, en el que el cicloalquilo, piperidina, tetrahidropirano, tetrahidrotiopirano, pirrolidina, tetrahidrofurano, indano y oxetano se sustituyen opcionalmente con un numero de sustituyentes de uno a tres seleccionados independientemente de entre los siguientes: alquilo, arilo y arilalquilo; uno de los radicales R5 o R6 es hidrogeno, isopropilo, isobutilo, cicloalquilo o haloalquilo y el otro es hidrogeno o no existe; y las sales y los ésteres farmacéuticamente aceptables de los mismos siempre que el 1,3-dihidro-4-fenil-1-(3-(trifiuorometil)fenil)-2H-imidazol-2-ona se excluya y, en el caso de que uno de los radicales R3 y sea metilo, etilo, n-propilo o n-butilo y el otro sea hidrogeno o no exista, entonces R2 no sea hidrogeno ni metilo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06122591 | 2006-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR063332A1 true AR063332A1 (es) | 2009-01-21 |
Family
ID=39259578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070104597A AR063332A1 (es) | 2006-10-19 | 2007-10-17 | Derivados de imidazolona e imidazolidinona como inhibidores de la 11b-hsd1, un proceso de preparacion y una composicion farmaceutica en base al compuesto |
Country Status (18)
Country | Link |
---|---|
US (1) | US8129423B2 (es) |
EP (2) | EP2308851A1 (es) |
JP (1) | JP5079011B2 (es) |
KR (2) | KR20110079776A (es) |
CN (1) | CN101553474B (es) |
AR (1) | AR063332A1 (es) |
AU (1) | AU2007312391B2 (es) |
BR (1) | BRPI0717657A2 (es) |
CA (1) | CA2666489C (es) |
CL (1) | CL2007002972A1 (es) |
IL (1) | IL197955A0 (es) |
MX (1) | MX2009003939A (es) |
NO (1) | NO20091548L (es) |
PE (1) | PE20080890A1 (es) |
RU (1) | RU2439062C2 (es) |
TW (1) | TWI339120B (es) |
WO (1) | WO2008046758A2 (es) |
ZA (1) | ZA200902638B (es) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007312390B2 (en) | 2006-10-19 | 2013-03-28 | F. Hoffmann-La Roche Ag | Aminomethyl-4-imidazoles |
MX2009003939A (es) | 2006-10-19 | 2009-05-11 | Hoffmann La Roche | Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes. |
EP2125750B1 (en) | 2007-02-26 | 2014-05-21 | Vitae Pharmaceuticals, Inc. | Cyclic urea and carbamate inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
CL2008001839A1 (es) | 2007-06-21 | 2009-01-16 | Incyte Holdings Corp | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2009034062A1 (en) * | 2007-09-11 | 2009-03-19 | Glaxo Group Limited | Compounds which inhibit the glycine transporter and uses thereof in medicine |
AR069207A1 (es) | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
JP5490014B2 (ja) | 2007-12-11 | 2014-05-14 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1型の環状尿素阻害剤 |
US8124636B2 (en) * | 2008-04-30 | 2012-02-28 | Hoffmann-La Roche Inc. | Imidazolidinone derivatives as 11B-HSD1 inhibitors |
JP5451752B2 (ja) * | 2008-05-01 | 2014-03-26 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター |
CL2009001058A1 (es) * | 2008-05-01 | 2010-09-10 | Vitae Pharmaceuticals Inc | Compuestos derivados de oxazinas sustituidas, inhibidores de la 11b-hidroxiesteroide deshidrogenasa de tipo-1; composicion farmaceutica; y uso del compuesto para inhibir la actividad de 11b-hsd1, como en el tratamiento de la diabetes, dislipidemia, hipertension, obesidad, cancer, glaucoma, entre otras. |
BRPI0911764A2 (pt) * | 2008-05-01 | 2015-10-06 | Boehringer Ingelheim Int | inibidores cíclicos de 11beta-hidroxiesteroide desigrogenase 1 |
CA2723034A1 (en) * | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
JP5658664B2 (ja) * | 2008-06-25 | 2015-01-28 | フォルム ファーマシューティカルズ、インコーポレイテッド | 1,2−二置換複素環式化合物 |
CA2729993A1 (en) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
TW201016691A (en) | 2008-07-25 | 2010-05-01 | Boehringer Ingelheim Int | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
US8114868B2 (en) | 2008-07-25 | 2012-02-14 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
WO2010089303A1 (en) | 2009-02-04 | 2010-08-12 | Boehringer Ingelheim International Gmbh | CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1 |
MA33216B1 (fr) | 2009-04-30 | 2012-04-02 | Boehringer Ingelheim Int | Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1 |
US8927539B2 (en) | 2009-06-11 | 2015-01-06 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure |
WO2011002910A1 (en) * | 2009-07-01 | 2011-01-06 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
US8552212B2 (en) | 2009-11-05 | 2013-10-08 | Boehringer Ingelheim International Gmbh | Chiral phosphorus ligands |
AR078887A1 (es) | 2009-11-06 | 2011-12-07 | Boehringer Ingelheim Int | Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina y composiciones farmaceuticas que los contienen. |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011149822A1 (en) | 2010-05-26 | 2011-12-01 | Boehringer Ingelheim International Gmbh | 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives |
EP2582698B1 (en) | 2010-06-16 | 2016-09-14 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
EP2585444B1 (en) | 2010-06-25 | 2014-10-22 | Boehringer Ingelheim International GmbH | Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
BR112013010021A2 (pt) | 2010-11-02 | 2019-09-24 | Boehringer Ingelheim Int | combinações farmacêuticas para o tratamento de distúrbios metabólicos. |
TWI537258B (zh) | 2010-11-05 | 2016-06-11 | 百靈佳殷格翰國際股份有限公司 | 六氫茚并吡啶及八氫苯并喹啉之芳基-及雜環芳基羰基衍生物 |
CN102241678B (zh) | 2011-04-26 | 2014-10-29 | 辽宁利锋科技开发有限公司 | 含有脂环结构化合物的抗肿瘤作用与应用 |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013134079A1 (en) | 2012-03-05 | 2013-09-12 | Amgen Inc. | Oxazolidinone compounds and derivatives thereof |
JP2015157764A (ja) * | 2012-06-14 | 2015-09-03 | 大正製薬株式会社 | グリシントランスポーター阻害物質 |
US8796305B2 (en) | 2012-11-05 | 2014-08-05 | Bayer Pharma Aktiengesellschaft | Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US8778964B2 (en) | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
US9624214B2 (en) | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US9126998B2 (en) | 2012-11-05 | 2015-09-08 | Bayer Pharma AG | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
CA2914100A1 (en) | 2013-06-04 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituted imidazo[1,2-a]pyridines and the use thereof |
US9422285B2 (en) | 2013-08-08 | 2016-08-23 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-A]-pyridine-3-carboxamides and use thereof |
CA2939793A1 (en) | 2014-02-19 | 2015-08-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines |
US9771360B2 (en) | 2014-03-21 | 2017-09-26 | Bayer Pharma Aktiengesellschaft | Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use |
GB201416346D0 (en) * | 2014-09-16 | 2014-10-29 | Shire Internat Gmbh | Spirocyclic derivatives |
CA2969268A1 (en) | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituted imidazo[1,2-a]pyridines and their use |
CA2969265A1 (en) | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines and their use |
CN107567446A (zh) | 2015-02-05 | 2018-01-09 | 拜耳制药股份公司 | 取代的吡唑并[1,5‑a]吡啶‑3‑甲酰胺及其用途 |
AR107434A1 (es) | 2016-01-13 | 2018-05-02 | Gruenenthal Gmbh | Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano |
WO2017121649A1 (en) | 2016-01-13 | 2017-07-20 | Grünenthal GmbH | 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives |
HUE051642T2 (hu) | 2016-01-13 | 2021-03-01 | Gruenenthal Gmbh | 8-amino-2-oxo-1,3-diaza-spiro-[4,5]-dekán származékok |
BR112018014303B1 (pt) | 2016-01-13 | 2023-10-03 | Grünenthal GmbH | Derivados de 3-((hetero-)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano |
MX2018008640A (es) | 2016-01-13 | 2018-11-19 | Gruenenthal Gmbh | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano. |
EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
RU2746423C2 (ru) * | 2019-09-02 | 2021-04-13 | Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар" (ООО "НИИ ХимРар") | Ингибитор вируса гепатита В (ВГВ) |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL24005A (en) * | 1964-12-31 | 1970-05-21 | Robins Co Inc A H | 1,3-disubstituted-4-(2-substituted-ethyl)-2-imidazolidinones,processes for their production and pharmaceutical compositions containing them |
GB1175820A (en) | 1966-02-18 | 1969-12-23 | Upjohn Co | Amino-Adamantane Derivatives |
US3625956A (en) * | 1967-12-08 | 1971-12-07 | Ciba Geigy Corp | 1-phenyl-4-alkyl-2-imidazolone derivatives |
CH547288A (de) * | 1971-06-23 | 1974-03-29 | Ciba Geigy Ag | Verfahren zur herstellung neuer heterocyclischer stoffe. |
GB9000725D0 (en) | 1990-01-12 | 1990-03-14 | Pfizer Ltd | Therapeutic agents |
US5164403A (en) | 1991-04-05 | 1992-11-17 | G. D. Searle & Co. | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders |
US5861420A (en) * | 1991-04-05 | 1999-01-19 | G. D. Searle & Co. | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders |
TW218017B (es) * | 1992-04-28 | 1993-12-21 | Takeda Pharm Industry Co Ltd | |
WO2002020493A2 (en) * | 2000-09-06 | 2002-03-14 | Chugai Seiyaku Kabushiki Kaisha | A traceless solid-phase synthesis of 2-imidazolones |
ATE548354T1 (de) * | 2002-07-24 | 2012-03-15 | Ptc Therapeutics Inc | Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen |
CN1980889B (zh) * | 2004-05-07 | 2010-11-10 | 詹森药业有限公司 | 11-β羟基类固醇脱氢酶抑制剂的金刚烷基吡咯烷-2-酮衍生物 |
CN101039908B (zh) * | 2004-08-30 | 2010-06-23 | 詹森药业有限公司 | 作为11-β羟甾类脱氢酶抑制剂的三环内酰胺衍生物 |
ES2386365T3 (es) * | 2005-01-05 | 2012-08-17 | Abbott Laboratories | Derivados de adamantilo como inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 |
US20090264650A1 (en) * | 2005-03-31 | 2009-10-22 | Nobuo Cho | Prophylactic/Therapeutic Agent for Diabetes |
EP1960368B1 (en) * | 2005-12-01 | 2015-05-06 | F. Hoffmann-La Roche AG | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents |
DOP2007000015A (es) | 2006-01-20 | 2007-08-31 | Quark Biotech Inc | Usos terapéuticos de inhibidores de rtp801 |
JP2007254409A (ja) * | 2006-03-24 | 2007-10-04 | Taisho Pharmaceut Co Ltd | イミダゾリジノン誘導体 |
WO2008044656A1 (fr) * | 2006-10-06 | 2008-04-17 | Taisho Pharmaceutical Co., Ltd. | Dérivé d'imidazolidinone |
MX2009003939A (es) | 2006-10-19 | 2009-05-11 | Hoffmann La Roche | Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes. |
CA2665255A1 (en) * | 2006-10-19 | 2008-04-24 | F. Hoffmann-La Roche Ag | Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors |
AU2007312390B2 (en) * | 2006-10-19 | 2013-03-28 | F. Hoffmann-La Roche Ag | Aminomethyl-4-imidazoles |
CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
-
2007
- 2007-10-09 MX MX2009003939A patent/MX2009003939A/es not_active Application Discontinuation
- 2007-10-09 EP EP10175995A patent/EP2308851A1/en not_active Withdrawn
- 2007-10-09 BR BRPI0717657-0A2A patent/BRPI0717657A2/pt not_active IP Right Cessation
- 2007-10-09 WO PCT/EP2007/060667 patent/WO2008046758A2/en active Application Filing
- 2007-10-09 EP EP07821040A patent/EP2104665A2/en not_active Withdrawn
- 2007-10-09 RU RU2009118488/04A patent/RU2439062C2/ru not_active IP Right Cessation
- 2007-10-09 KR KR1020117013229A patent/KR20110079776A/ko not_active Application Discontinuation
- 2007-10-09 KR KR1020097007936A patent/KR101118410B1/ko not_active IP Right Cessation
- 2007-10-09 JP JP2009532768A patent/JP5079011B2/ja not_active Expired - Fee Related
- 2007-10-09 CN CN2007800387224A patent/CN101553474B/zh not_active Expired - Fee Related
- 2007-10-09 CA CA2666489A patent/CA2666489C/en not_active Expired - Fee Related
- 2007-10-09 AU AU2007312391A patent/AU2007312391B2/en not_active Ceased
- 2007-10-12 US US11/871,318 patent/US8129423B2/en not_active Expired - Fee Related
- 2007-10-16 TW TW096138731A patent/TWI339120B/zh not_active IP Right Cessation
- 2007-10-17 AR ARP070104597A patent/AR063332A1/es not_active Application Discontinuation
- 2007-10-17 PE PE2007001408A patent/PE20080890A1/es not_active Application Discontinuation
- 2007-10-17 CL CL200702972A patent/CL2007002972A1/es unknown
-
2009
- 2009-04-05 IL IL197955A patent/IL197955A0/en unknown
- 2009-04-16 ZA ZA200902638A patent/ZA200902638B/xx unknown
- 2009-04-20 NO NO20091548A patent/NO20091548L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2008046758A3 (en) | 2009-06-11 |
NO20091548L (no) | 2009-05-05 |
MX2009003939A (es) | 2009-05-11 |
KR20110079776A (ko) | 2011-07-07 |
WO2008046758A2 (en) | 2008-04-24 |
JP2010506876A (ja) | 2010-03-04 |
CL2007002972A1 (es) | 2008-05-30 |
US8129423B2 (en) | 2012-03-06 |
CN101553474A (zh) | 2009-10-07 |
US20080103183A1 (en) | 2008-05-01 |
TWI339120B (en) | 2011-03-21 |
EP2308851A1 (en) | 2011-04-13 |
PE20080890A1 (es) | 2008-06-28 |
KR20090065535A (ko) | 2009-06-22 |
AU2007312391A1 (en) | 2008-04-24 |
CA2666489C (en) | 2012-10-02 |
CA2666489A1 (en) | 2008-04-24 |
IL197955A0 (en) | 2009-12-24 |
AU2007312391B2 (en) | 2012-06-21 |
EP2104665A2 (en) | 2009-09-30 |
JP5079011B2 (ja) | 2012-11-21 |
KR101118410B1 (ko) | 2012-04-23 |
RU2009118488A (ru) | 2010-11-27 |
ZA200902638B (en) | 2010-03-31 |
BRPI0717657A2 (pt) | 2013-12-24 |
RU2439062C2 (ru) | 2012-01-10 |
TW200831088A (en) | 2008-08-01 |
CN101553474B (zh) | 2013-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR063332A1 (es) | Derivados de imidazolona e imidazolidinona como inhibidores de la 11b-hsd1, un proceso de preparacion y una composicion farmaceutica en base al compuesto | |
AR059984A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa -iv para el tratamiento o prevencion de diabetes | |
AR069796A1 (es) | Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen | |
AR071512A1 (es) | Derivados de imidazolidinona como inhibidores de 11b-hsd1 | |
AR043049A1 (es) | Derivados de hidantoina, proceso de preparacion del mismo y composicion farmaceutica | |
ECSP099324A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
AR049739A1 (es) | Derivados de aril-piridina | |
AR080865A1 (es) | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. | |
AR040626A1 (es) | Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy) | |
NO20080456L (no) | Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer | |
AR084913A1 (es) | Derivados de aril-benzocicloalquil-amida | |
AR044152A1 (es) | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad | |
AR073314A1 (es) | Derivados de indazol o de 4,5,6,7-tetrahidro-indazol | |
AR065322A1 (es) | 2-aminooxazolinas comoligandos de taar1 | |
RU2009102535A (ru) | Производные карбамидов тропана, их получение и их применение в терапии | |
DK1786790T3 (da) | Oxazolderivater som histamin H3 receptorstoffer, fremstilling og terapeutiske anvendelser | |
AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
CO6140059A2 (es) | Derivados de imidazol-pirimidina para el tratamiento de enfermedades relacionadas con la glicogeno sintasa quinasa (gsk3) | |
PE20090820A1 (es) | Derivados de piperidina/piperazina | |
NO20063597L (no) | Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
AR060593A1 (es) | 5-amido-2-carboxiamida-indoles | |
AR083798A1 (es) | Inhibidores selectivos de glucosidasas y sus usos | |
AR064729A1 (es) | Derivados de 2,4-dianilinopirimidinas, su preparacion, composiciones farmaceuticas y usos como inhibidores de ikk | |
AR057887A1 (es) | Composiciones y metodos de tratamiento de trastornos del snc | |
AR075229A1 (es) | Derivados de dihidroquinolinona. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |